Skip to main content
SpringerLink
Log in

Clinical Pharmacokinetics of Dorzolamide

  • Review Articles
  • Drug Disposition
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Abstract

Dorzolamide is a carbonic anhydrase inhibitor for topical ophthalmic application. It is used in the treatment of glaucoma to lower the intraocular pressure. After absorption via the cornea and stroma, it inhibits carbonic anhydrase in the ciliary process, which leads to a reduction of aqueous humour production and therefore to the desired therapeutic effect. In the systemic circulation, dorzolamide is bound mainly to carbonic anhydrase in red blood cells. It is slowly metabolised to N-de-ethyldorzolamide, which in turn is also stored in red blood cells. The very slow elimination (half-life >4 months) of both substances takes place via the renal route. However, the inhibition of carbonic anhydrase in red blood cells is moderate in the course of a topical treatment, avoiding systemic adverse effects.

This review summarises the pharmacokinetic and pharmacodynamic properties of dorzolamide and its metabolite in eye tissues and in the systemic circulation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Fig. 2
Table II

Similar content being viewed by others

References

  1. Biollaz J, Munafo A, Buclin T, et al. Whole-blood pharmacokinetics and metabolic effects of the topical carbonic anhydrase inhibitor dorzolamide. Eur J Clin Pharmacol 1995; 47: 453–60

    Article  Google Scholar 

  2. Pfeiffer N. Rückblick zur Glaukomforschung. Klin Monatsbl Augenheilkd 1993; 203: 1–9

    Article  PubMed  CAS  Google Scholar 

  3. Pfeiffer N. Dorzolamide: development and clinical application of a topical carbonic anhydrase inhibitor. Surv Ophthalmol 1997; 42: 137–51

    Article  PubMed  CAS  Google Scholar 

  4. Donohue EK, Wilensky JT. Trusopt. Atopical carbonic anhydrase inhibitor. J Glaucoma 1996; 5: 68–74

    Article  PubMed  CAS  Google Scholar 

  5. Drake MV. New medical therapies for glaucoma. Int Ophthalmol Clin 1996; 36: 53–60

    Article  PubMed  CAS  Google Scholar 

  6. Serle JB. Pharmacological advances in the treatment of glaucoma. Drugs Aging 1994; 5: 156–70

    Article  PubMed  CAS  Google Scholar 

  7. Moroi SE, Lichter PR. Ocular pharmacology. In: Goodman and Gilman’s the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 1619–45

    Google Scholar 

  8. Maren TH, Conroy CW, Wynns GC, et al. Ocular absorption, blood levels, and excretion of dorzolamide, a topically active carbonic anhydrase inhibitor. J Ocul Pharmacol Ther 1997; 13: 23–30

    Article  PubMed  CAS  Google Scholar 

  9. Schmitz K, Banditt P, Motschman M, et al. Population pharmacokinetics of 2% topical dorzolamide in the aqueous humor of humans. Invest Ophthalmol Vis Sci 1999; 40: 1621–4

    PubMed  CAS  Google Scholar 

  10. Bauer NJC, Motamedi M, Wicksted JP, et al. Non-invasive assessment of ocular pharmacokinetics using confocal raman spectroscopy. J Ocul Pharmacol Ther 1999; 15: 123–34

    Article  PubMed  CAS  Google Scholar 

  11. Schoenwald RD, Deshpande GS, Rethwisch DG, et al. Penetration into the anterior chamber via the conjunctival/scleral pathway. J Ocul Pharmacol Ther 1997; 13: 41–59

    Article  PubMed  CAS  Google Scholar 

  12. Spuran CT, Scozzafave A, Menabuoni L, et al. Carbonic anhydrase inhibitors. Pt 71. Synthesis and ocular pharmacology of a new class of water-soluble, topically effective intraocular pressure lowering sulfonamides incorporating picolinoyl moieties. Eur J Pharm Sci 1999; 8: 317–28

    Article  Google Scholar 

  13. Scozzafava A, Menabuoni L, Mincione F, et al. Carbonic anhydrase inhibitors. Synthesis of water-soluble, topically effective, intraocular pressure-lowering aromatic/heterocyclic sulfonamides containing cationic or anionic moieties: is the tail more important than the ring? J Med Chem 1999; 42: 2641–50

    Article  PubMed  CAS  Google Scholar 

  14. Ponicello GS, Sugrue MF, Plazonnet B, et al. Dorzolamide, a 40-year wait. Pharm Biotechnol 1998; 11: 555–74

    Article  Google Scholar 

  15. Sugrue MF. Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors. Prog Retin Eye Res 2000; 19: 87–112

    Article  PubMed  CAS  Google Scholar 

  16. Sugrue MF. The preclinical pharmacology of dorzolamide hydrochloride, a topical carbonic anhydrase inhibitor. J Ocul Pharmacol Ther 1996; 12: 363–76

    Article  PubMed  CAS  Google Scholar 

  17. Conroy CW. Sulfonamides do not reach the retina in therapeutic amounts after topical application to the cornea. J Ocular Pharmacol Therap 1997; 13: 465–72

    Article  CAS  Google Scholar 

  18. Lee VHL, Robinson JR. Topical ocular drug delivery: recent developments and future challenges. J Ocul Pharmacol 1986; 2: 67–108

    Article  PubMed  CAS  Google Scholar 

  19. Balfour JA, Wilde MI. Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension. Drugs Aging 1997; 10: 384–403

    Article  PubMed  CAS  Google Scholar 

  20. Hasegawa T, Hara K, Kenmochi T, et al. In vitro metabolism of dorzolamide, a novel potent carbonic anhydrase inhibitor, in rat liver microsomes. Drug Metab Dispos 1994; 22: 916–21

    PubMed  CAS  Google Scholar 

  21. Matuszewski BK, Constanzer ML. Indirect chiral separation and analyses in human biological fluids of the stereoisomers ofa thienothiopyran-2-sulfonamide (TRUSOPT), a novel carbonic anhydrase inhibitor with two chiral centers in the molecule. Chirality 1992; 4: 515–9

    Article  PubMed  CAS  Google Scholar 

  22. Maren TH. Carbonic anhydrase: chemistry, physiology, and inhibition. Physiol Rev 1967; 47: 595–781

    PubMed  CAS  Google Scholar 

  23. Hasegawa T, Hara K, Hata S. Binding of dorzolamide and its metabolite, N-deethylated dorzolamide, to human erythrocytes in vitro. Drug Metab Dispos 1994; 10: 377–82

    Google Scholar 

  24. Strahlman E, Tipping R, Vogel R. A six-week dose-response study of the ocular hypotensive effect of dorzolamide with a one-year extension. Am J Ophthalmol 1996; 122: 183–94

    PubMed  CAS  Google Scholar 

  25. Wilkerson M, Cyrlin M, Lippa EA, et al. Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor. Arch Ophthalmol 1993; 111: 1343–9

    Article  PubMed  CAS  Google Scholar 

  26. Matuszewski BK, Constanzer ML, Woolf EJ, et al. Determination of MK-507, a novel topically effective carbonic anhydrase inhibitor, and its de-ethylated metabolite in human whole blood, plasma, and urine by high-performance liquid chromatography. J Chromatogr Biomed Appl 1994; 653: 77–85

    Article  CAS  Google Scholar 

  27. Wong BK, Bruhin PJ, Barrish A, et al. Nonlinear dorzolamide pharmacokinetics in rats: concentration-dependent erythrocyte distribution and drug-metabolite displacement interaction. Drug Metab Dispos 1996; 24: 659–63

    PubMed  CAS  Google Scholar 

  28. Constanzer ML, Chavez CM, Matuszewski BK. Low level determination of dorzolamide and its de-ethylated metabolite in human plasma by liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry. J Pharm Biomed Anal 1997; 15: 1001–8

    Article  PubMed  CAS  Google Scholar 

  29. Maren TH, Wiley C. The in vitro activity of sulfonamides against red cell carbonic anhydrases: effect of ionic and substrate variation on the hydration reaction. J Med Chem 1968; 11: 228–32

    Article  PubMed  CAS  Google Scholar 

  30. Taylor PW, King RW, Burgen ASV. Influence of pH on the kinetics of complex formation between aromatic sulfonamides and human carbonic anhydrase. Biochemistry 1970; 9: 3894–902

    Article  PubMed  CAS  Google Scholar 

  31. Conroy CW, Maren TH. The effect of temperature on the binding of sulfonamides to carbonic anhydrase isoenzymes I, II and IV. Mol Pharmacol 1995; 48: 486–91

    PubMed  CAS  Google Scholar 

  32. Supuran CT, Scozzafava A, Saramet I, et al. Carbonic anhydrase inhibitors: inhibition of isozymes I, II and IV with heterocyclic mercaptans, sulfenamides, sulfonamides and their metal complexes. J Enzyme Inhib 1998; 13: 177–94

    Article  PubMed  CAS  Google Scholar 

  33. Mincione F, Menabuoni L, Briganti F, et al. Carbonic anhydrase inhibitors: inhibition of isozymes I, II and IV with N-hydroxysulfonamides — a novel class of intraocular pressure lowering agents. J Enzyme Inhib 1998; 13: 267–84

    Article  PubMed  CAS  Google Scholar 

  34. Landolfi C, Marchetti M, Giocci G, et al. Development and pharmacological characterization of a modified procedure for the measurement of carbonic anhydrase activity. J Pharmacol Toxicol Methods 1997; 38: 169–72

    Article  PubMed  CAS  Google Scholar 

  35. Sugrue MF, Mallorga P, Schwam H, et al. A comparison of L-671,152 and MK-927, two topically effective ocular hypotensive carbonic anhydrase inhibitors, in experimental animals. Curr Eye Res 1990; 9: 607–15

    Article  PubMed  CAS  Google Scholar 

  36. Maren TH. The development of topical carbonic anhydrase inhibitors. J Glaucoma 1995; 4: 49–62

    Article  PubMed  CAS  Google Scholar 

  37. Hagemann GS, Zhu XL, Waheed A, et al. Localization of carbonic anhydrase IV in a specific capillary bed of the human eye. Proc Natl Acad Sci U S A 1991; 88: 2716–20

    Article  Google Scholar 

  38. Krupin T, Sly WS, Whyte MP, et al. Failure of acetazolamide to decrease intraocular pressure in patients with carbonic an-hydrase II deficiency. Am J Ophthalmol 1985; 99: 396–9

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Dedicated to Professor Dr F.P. Meyer for his 65th birthday.

Author information

Authors and Affiliations

  1. Institute of Clinical Pharmacology, Otto-von-Guericke University, Magdeburg, Germany

    Jens Martens-Lobenhoffer & Peter Banditt

Authors
  1. Jens Martens-Lobenhoffer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Banditt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jens Martens-Lobenhoffer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Martens-Lobenhoffer, J., Banditt, P. Clinical Pharmacokinetics of Dorzolamide. Clin Pharmacokinet 41, 197–205 (2002). https://doi.org/10.2165/00003088-200241030-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-200241030-00004

Keywords

Search

Navigation